semaglutide US list prices, may 2026: ozempic ~$936/month, wegovy ~$1,349/month, rybelsus ~$936/month. with commercial insurance covering wegovy for obesity, out-of-pocket runs $25-200/month using Novo's SaveCard. medicare excludes anti-obesity drugs as a class (limited cardiovascular-risk exception post-SELECT). compounded semaglutide runs $200-400/month, but the april 2026 FDA 503B proposal would close most legal compounding pathways.
the actual cost depends on four variables: which formulation, what your insurance covers, whether you're eligible for assistance programs, and whether the regulatory ground keeps moving. start with the calculator below for your scenario, then read on for the layers.
what each formulation costs without insurance.
wholesale acquisition cost (WAC) figures, the published price before any rebates, insurance, or assistance:
what the other ~$1,250 covers.
click any segment to drill into where each dollar goes.
none of this is unique to semaglutide. it's how every patent-protected blockbuster drug is priced in the US. the difference is scale: ~10M Americans on GLP-1s by 2025 means semaglutide alone is one of the largest drug spends in US healthcare history.
what most commercial plans cover.
coverage depends on indication and plan structure. broadly:
ozempic for type 2 diabetes: covered by most commercial plans. typical out-of-pocket: $25-100/month after copay. some plans require step therapy (try metformin and sulfonylurea first).
wegovy for obesity: variable. ~50% of commercial plans cover it as of mid-2026. typical requirements: BMI ≥30 (or ≥27 with comorbidity), prior failure on lifestyle programs, prior auth. typical out-of-pocket: $25-200/month with Novo's SaveCard.
wegovy for cardiovascular risk reduction: the SELECT-based label addition (march 2024) is shifting coverage. cardiologists can prescribe wegovy for established CVD plus obesity/overweight. some plans now cover this indication even when they don't cover wegovy for general obesity.
ozempic off-label for weight loss: typically not covered. plans treat off-label as patient-pay.
why medicare doesn't cover semaglutide for obesity.
the Medicare Modernization Act of 2003 explicitly excluded anti-obesity drugs from medicare part D coverage. that was 21 years before the GLP-1 obesity trials reset what's possible. as of 2026, medicare beneficiaries on wegovy for obesity pay the full ~$1,349/month list price unless they qualify for one of two carve-outs:
1. wegovy for cardiovascular risk reduction. after the SELECT-based label addition (march 2024), medicare part D plans can cover wegovy for adults with established cardiovascular disease and obesity/overweight, even though the underlying obesity drug exclusion remains.
2. ozempic for diabetes. covered as a diabetes drug. patients use the diabetes coverage even when weight loss is the actual goal.
legislation to add anti-obesity drugs to medicare coverage (the Treat and Reduce Obesity Act, TROA) has been proposed in every congress since 2013 and has not passed. CBO scoring estimates put the 10-year cost at $35-50B. the political math has not yet moved.
savings programs that actually work.
novo runs three patient assistance programs for semaglutide products. the requirements and savings are specific:
wegovy SaveCard. for commercially insured patients with coverage. caps copay at $25/month for up to 12 months. requires commercial insurance (not medicare/medicaid).
wegovy cash-pay program. for patients without insurance coverage, novo's NovoCare program sells wegovy pens at $349/month from 0.25 mg to 2.4 mg and $399/month for Wegovy HD 7.2 mg as of october 25, 2026, and new patients pay $199 for each of their first 2 monthly fills at 0.25 mg or 0.5 mg through december 31, 2026 (list price is $1,349.02 a package; the program started at $499/month in march 2025, after an earlier $650 NovoCare tier). on NovoCare the Wegovy pill is $149 to $299 a month by dose. Wegovy HD 7.2 mg ships at roughly $399/month via GoodRx since april 2026. enrollment requires a prescription and verification of no insurance coverage for the drug.
ozempic SaveCard. commercial-insured patients with diabetes coverage cap at $25/month for the first 24 months. similar restrictions to the wegovy SaveCard.
these programs are real, but stocking varies by pharmacy. small independent pharmacies often don't process SaveCards consistently. CVS, walgreens, and walmart pharmacies handle them more reliably.
the compounded semaglutide pricing tier.
from late 2022 through february 2025, the FDA listed semaglutide as in shortage, which legally allowed 503B outsourcing facilities and 503A compounding pharmacies to produce compounded versions. typical compounded semaglutide pricing during that window:
503B compounded: $200-400/month, depending on dose and pharmacy.
telehealth bundles: many telehealth companies offered compounded semaglutide at $300-500/month including consultations and shipping.
the FDA removed semaglutide from the shortage list in february 2025. compounding under the shortage exception ended. the industry shifted to "patient-specific" or "personalized" formulations to keep selling under different regulatory carve-outs (503A pharmacies producing for individual prescriptions).
on april 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. if finalized, that would close most 503B compounded-GLP-1 pathways for these molecules (503A single-patient compounded prescriptions remain legal under separate authority). the comment period closes june 29, 2026.
what semaglutide costs outside the US.
US pricing in context. same drug, dramatically different prices on private prescription, may 2026:
the US-vs-everywhere-else gap is the largest documented for any blockbuster drug class. patients near borders (canada, mexico) sometimes import at lower prices, though FDA personal-import policies are unclear.
published list prices are for the drug only. the full clinical cost includes:
titration phase wasted product. the 0.25 mg starting dose is below therapeutic. patients pay full price for 4 weeks of subtherapeutic dosing, then pay for each escalation step. total wasted-product cost over the 16-20 week titration: roughly $400-1,200 depending on insurance.
lab tests. baseline metabolic panel, A1C, lipid panel, sometimes thyroid panel. ~$100-300 if not covered.
follow-up visits. most prescribers want monthly check-ins during titration, then quarterly. ~$100-300 per visit if specialist, less if primary care.
GI symptom management. ondansetron prescriptions for nausea, dietary changes during titration. variable.
discontinuation regain. trial data shows patients regain a meaningful fraction of lost weight after stopping. the chronic-disease pattern means stopping is rarely a final exit, and re-titration restarts the cost cycle.
the chronic-disease cost framing.
semaglutide is increasingly framed by clinicians as a chronic-disease treatment, like statins or antihypertensives. that means the realistic cost calculation is annual, not one-time:
year 1, with insurance + SaveCard: ~$300-2,400 (mostly copays). titration phase included.
year 1, cash pay novocare: ~$4,188 ($349/month × 12 at NovoCare's price for pens up to 2.4 mg as of october 25, 2026), or ~$3,888 if the first 2 fills get the $199 new-patient price.
year 1, list price no assistance: ~$16,200. ($1,349/month × 12).
year 1, compounded (while available): ~$2,400-4,800.
if the chronic-disease framing holds, those numbers compound across decades. that's the political math behind the medicare coverage debate.
questions people actually ask.
what does semaglutide cost? branded wegovy and ozempic list around $936 to $1,349 a month in 2026. for insured patients, manufacturer savings programs (NovoCare, SaveCard) and pharmacy pricing lower the out-of-pocket cost. semaglutide is a prescription medication, obtained through a licensed prescriber and pharmacy.
does insurance cover ozempic for weight loss? rarely. ozempic is approved for type 2 diabetes, and plans treat off-label use for weight loss as patient-pay, even when the prescriber writes the prescription.
will medicare ever cover wegovy for obesity? uncertain. the underlying anti-obesity drug exclusion in the Medicare Modernization Act has not been repealed despite multiple attempts (TROA legislation since 2013). the SELECT cardiovascular indication is the existing carve-out.
is canadian or mexican semaglutide cheaper? yes. wegovy in canada is ~$295/month, in mexico ~$245/month. FDA personal-import enforcement varies. confirm policies for your situation.
are compounded versions safe? the molecule is identical when the compounding is done correctly. quality control varies by pharmacy. the FDA has flagged unverified online vendors. if you use a compounder, use an established 503A pharmacy with state board licensure, not a generic online seller.
how long does the wegovy SaveCard last? 12 months for commercial-insured patients with coverage. extension programs exist but are not guaranteed.
what happens if i lose insurance coverage mid-treatment? options: switch to novocare cash pay ($349/month for wegovy pens up to 2.4 mg and $399/month for Wegovy HD 7.2 mg as of october 25, 2026), Wegovy HD via GoodRx ($399/month since april 2026), switch to compounded (if available), or discontinue. discontinuation typically results in weight regain over 6-12 months per SURMOUNT-4 / STEP 4 patterns.
reptides editorial · research reference, not medical advice.